Treatment with intravenous iron and ferritin level
TRATAMIENTO CON HIERRO INTRAVENOSO Y NIVEL DE FERRITINA
Read
10139
Timeswas read the article
2293
Total PDF
7846
Total HTML
Share statistics
array:21 [ "pii" => "X201325141003575X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Mar.10258" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:371-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4596 "formatos" => array:3 [ "EPUB" => 289 "HTML" => 3738 "PDF" => 569 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699510035752" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2010.Mar.10258" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2010;30:371-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10788 "formatos" => array:3 [ "EPUB" => 282 "HTML" => 9891 "PDF" => 615 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "TRATAMIENTO CON HIERRO INTRAVENOSO Y NIVEL DE FERRITINA" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "371" "paginaFinal" => "372" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Treatment with intravenous iron and ferritin level" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Fernández-Gallego, María Adoración Martín, Seema Sujan, Encarnacion Vega" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Juan" "apellidos" => "Fernández-Gallego" ] 1 => array:2 [ "nombre" => "María Adoración" "apellidos" => "Martín" ] 2 => array:2 [ "nombre" => "Seema" "apellidos" => "Sujan" ] 3 => array:2 [ "nombre" => "Encarnacion" "apellidos" => "Vega" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X201325141003575X" "doi" => "10.3265/Nefrologia.pre2010.Mar.10258" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141003575X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035752?idApp=UINPBA000064" "url" => "/02116995/0000003000000003/v0_201502091325/X0211699510035752/v0_201502091326/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251410035709" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Mar.10310" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:372-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4248 "formatos" => array:3 [ "EPUB" => 314 "HTML" => 3350 "PDF" => 584 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Methoxy polyethylene glycol-epoetin beta in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "372" "paginaFinal" => "373" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "METOXI-POLIETILENGLICOL EPOETINA BETA (MIRCERA®) EN EL TRATAMIENTO DE UNA PACIENTE CON ENFERMEDAD RENAL CRÓNICA Y QUE PRESENTA HIPERSENSIBILIDAD RETARDADA A OTRAS EPOETINAS" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Cristina Lucía Dávila Fajardo, María Peña Ortega, José Cabeza Barrera, Mª Dolores Prados Garrido" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Cristina Lucía" "apellidos" => "Dávila Fajardo" ] 1 => array:2 [ "nombre" => "María" "apellidos" => "Peña Ortega" ] 2 => array:2 [ "nombre" => "José" "apellidos" => "Cabeza Barrera" ] 3 => array:2 [ "nombre" => "Mª Dolores" "apellidos" => "Prados Garrido" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699510035701" "doi" => "10.3265/Nefrologia.pre2010.Mar.10310" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035701?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035709?idApp=UINPBA000064" "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035709/v0_201502091604/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251410035686" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Mar.10273" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:370-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3243 "formatos" => array:3 [ "EPUB" => 284 "HTML" => 2446 "PDF" => 513 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Change in regulations for dispensing immunosppressants to patients who have undergone a kidney transplant" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "370" "paginaFinal" => "371" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "CAMBIO EN LA NORMATIVA DE DISPENSACIÓN DE INMUNOSUPRESORES EN EL TRASPLANTADO RENAL" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jaime Gulín Dávila, Inmaculada López Rodríguez" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jaime" "apellidos" => "Gulín Dávila" ] 1 => array:2 [ "nombre" => "Inmaculada" "apellidos" => "López Rodríguez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699510035689" "doi" => "10.3265/Nefrologia.pre2010.Mar.10273" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035689?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035686?idApp=UINPBA000064" "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035686/v0_201502091604/en/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Treatment with intravenous iron and ferritin level" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "371" "paginaFinal" => "372" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Juan Fernández-Gallego, María Adoración Martín, Seema Sujan, Encarnacion Vega" "autores" => array:4 [ 0 => array:3 [ "nombre" => "Juan" "apellidos" => "Fernández-Gallego" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "María Adoración" "apellidos" => "Martín" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "nombre" => "Seema" "apellidos" => "Sujan" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "nombre" => "Encarnacion" "apellidos" => "Vega" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Carlos Haya, Málaga, Málaga, España, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "TRATAMIENTO CON HIERRO INTRAVENOSO Y NIVEL DE FERRITINA" ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold"> Dear Editor, </span> </p><p class="elsevierStylePara"> The 2006 K/DOQI guidelines on anaemia in patients on chronic haemodialysis (HD) indicate that treatment should be done with IV Fe in order to maintain a ferritin (FER) value of more than 200- 500μg/l to achieve adequate erythropoiesis.<span class="elsevierStyleSup">1 </span>Other studies<span class="elsevierStyleSup">2,3 </span>state that FER should be kept in a higher range, but there are no controlled studies comparing the efficacy as measured by the Hb, EPO dose, and iatrogenic sequelae<span class="elsevierStyleSup">4,5 </span>in groups of patients with FER values above and below 500, with maximum values greater than 500 indicating high doses of IV Fe. Recent research shows that administration of low dose IV Fe on a continual basis causes increased protein oxidation, something that does not happen often with intermittent treatment.<span class="elsevierStyleSup">6 </span> </p><p class="elsevierStylePara"> The purpose of this prospective observational case-control study is to evaluate, in 10 patients on HD, if the Hb and EPO dose changed with IV Fe administration in two different treatment protocols, lasting six months each. Patients were included after ruling out factors affecting erythropoiesis for six months before and during the study (transfusion, infection, inflammation, malnutrition, surgery, hospitalisation, severe hyperparathyroidism, etc.). <span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> FER1 Protocol. </span>Treated with 50mg Fe sucrose IV/1 HD session, 8 HD in a row (400mg) to achieve and maintain a maximum FER value greater than and close to 300μg/l; data collection six months before the start of the FER2 protocol. <span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold"> FER2 Protocol. </span>Treated with 25 mg Fe sucrose IV/1 weekly HD session for 16 weeks in a row (400mg) to achieve and maintain a maximum FER value greater than and close to 300μg/l; data collection from the fourth month of starting. FER was assessed, then 2 months to assess continued treatment in the two protocols, and we did not treat with IV Fe if there was an acute infection.  </p><p class="elsevierStylePara"> In each protocol we assessed: intact PTH/3 months, balanced KTV (Daugirdas)/month, albumin g/l/3 months, subjective global assessment of nutrition, PCR/3 months, Hb/month, EPO dose in units/kg/week, ferritin/2 months, total dose of IV Fe in mg/patient/6 months (Fe 6), total dose of IV Fe in mg/patient/1 month (Fe 1), range in mg/patient of Fe 6 (range Fe 6). Age (75 ± 12 years), female sex (40%), HD time in months and with vascular access, and high-flow membranes were similar. There was no statistically significant difference in PTH (268 ± 249, FER1 vs. 297 ± 198, FER2), eKTV (1.37 ± 0.1, FER1 vs. 1.34 ± 0.1, FER2), albumin (36.3 ± 3, FER1 versus 35.4 ± 3, FER2), mild malnutrition in both groups, CRP (11.4 ± 9, FER1 vs. 13 ± 11, FER2), or in the main variables: Hb (12.4 ± 0.4, FER1 versus 12.3 ± 0.3, FER2), EPO (99 ± 51, FER1 vs. 85 ± 46, FER2), Fe 6 (854 ± 204mg, FER1 vs. 598 ± 126, FER2), Fe 1 (142 ± 34mg, FER1 vs. 99 ± 21, FER2) and Fe 6 range (500- 1100mg, FER1 vs. 400 to 800mg, FER2), but there was a difference with p < 0.05 in FER (332 ± 24, FER1 vs. 225 ± 37, FER2).  </p><p class="elsevierStylePara"> This prospective observational casecontrol study of patients on HD shows that Hb, EPO dose, and dose of IV Fe administered with the two protocols (FER maximum range greater than and close to 300μg/l vs FER maximum value of less than and close to 300) do not change. Prior scientific evidence<span class="elsevierStyleSup">1,4 </span>and data from this research suggest achieving adequate erythropoiesis when treating with IV Fe, reducing iatrogenic sequelae,<span class="elsevierStyleSup">4,5 </span>and keeping the maximum FER greater than or less than and close to 300μg/l. Based on current evidence,<span class="elsevierStyleSup">6 </span>it would be advisable to treat intermittently with low dose Fe. <span class="elsevierStyleBold"> </span></p>" "pdfFichero" => "P1-E46-S1860-A10258-EN.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:6 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults: CPG and CPR 3.2: Using iron agents. Am J Kidney Dis. 2006. \u{A0}47 (Suppl 3): S 58-S 70." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NW, Rizkala AR, and the DRIVE STUDY GROUP: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007. \u{A0}18: 975-984. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17267740" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Singh AK, Coyne DW, Shapiro W, Rizkala AR, the DRIVE Study Group: Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007. \u{A0}71: 1163-1171. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17396118" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A: Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int. 2004.\u{A0}65: 1091-1098. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14871430" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bishu K, Agarwal R: Iron deficiency in the 2006 K/DOQI era: Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol. 2006.\u{A0}1: (Suppl 1): S 19- S 23." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "6.Anraku M, Kitamura K, Shintomo\u{A0} R, Takeuchi K,Ikeda H, Nagano J, Ko T, Mera K, Tomita K, Otagiri M. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: A pilot study. Clin Biochem.2008.41: 1168-1174. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18692036" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003000000003/v0_201502091603/X201325141003575X/v0_201502091604/en/main.assets" "Apartado" => array:4 [ "identificador" => "35436" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003000000003/v0_201502091603/X201325141003575X/v0_201502091604/en/P1-E46-S1860-A10258-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141003575X?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 8 | 8 | 16 |
| 2024 October | 74 | 33 | 107 |
| 2024 September | 82 | 23 | 105 |
| 2024 August | 92 | 52 | 144 |
| 2024 July | 56 | 30 | 86 |
| 2024 June | 84 | 43 | 127 |
| 2024 May | 59 | 44 | 103 |
| 2024 April | 60 | 51 | 111 |
| 2024 March | 45 | 30 | 75 |
| 2024 February | 45 | 27 | 72 |
| 2024 January | 37 | 24 | 61 |
| 2023 December | 42 | 26 | 68 |
| 2023 November | 61 | 28 | 89 |
| 2023 October | 89 | 32 | 121 |
| 2023 September | 71 | 39 | 110 |
| 2023 August | 45 | 14 | 59 |
| 2023 July | 68 | 25 | 93 |
| 2023 June | 41 | 20 | 61 |
| 2023 May | 55 | 27 | 82 |
| 2023 April | 54 | 23 | 77 |
| 2023 March | 63 | 17 | 80 |
| 2023 February | 43 | 18 | 61 |
| 2023 January | 49 | 31 | 80 |
| 2022 December | 59 | 37 | 96 |
| 2022 November | 71 | 38 | 109 |
| 2022 October | 66 | 76 | 142 |
| 2022 September | 70 | 45 | 115 |
| 2022 August | 96 | 43 | 139 |
| 2022 July | 74 | 42 | 116 |
| 2022 June | 81 | 37 | 118 |
| 2022 May | 77 | 31 | 108 |
| 2022 April | 78 | 50 | 128 |
| 2022 March | 103 | 54 | 157 |
| 2022 February | 112 | 57 | 169 |
| 2022 January | 58 | 39 | 97 |
| 2021 December | 55 | 40 | 95 |
| 2021 November | 59 | 30 | 89 |
| 2021 October | 84 | 43 | 127 |
| 2021 September | 41 | 26 | 67 |
| 2021 August | 73 | 33 | 106 |
| 2021 July | 73 | 27 | 100 |
| 2021 June | 47 | 24 | 71 |
| 2021 May | 60 | 26 | 86 |
| 2021 April | 172 | 49 | 221 |
| 2021 March | 112 | 51 | 163 |
| 2021 February | 122 | 19 | 141 |
| 2021 January | 73 | 15 | 88 |
| 2020 December | 86 | 13 | 99 |
| 2020 November | 77 | 8 | 85 |
| 2020 October | 65 | 15 | 80 |
| 2020 September | 88 | 8 | 96 |
| 2020 August | 73 | 5 | 78 |
| 2020 July | 87 | 15 | 102 |
| 2020 June | 91 | 10 | 101 |
| 2020 May | 85 | 13 | 98 |
| 2020 April | 63 | 21 | 84 |
| 2020 March | 106 | 13 | 119 |
| 2020 February | 93 | 15 | 108 |
| 2020 January | 105 | 20 | 125 |
| 2019 December | 100 | 18 | 118 |
| 2019 November | 106 | 21 | 127 |
| 2019 October | 49 | 9 | 58 |
| 2019 September | 72 | 26 | 98 |
| 2019 August | 57 | 20 | 77 |
| 2019 July | 49 | 18 | 67 |
| 2019 June | 57 | 22 | 79 |
| 2019 May | 40 | 11 | 51 |
| 2019 April | 96 | 28 | 124 |
| 2019 March | 133 | 24 | 157 |
| 2019 February | 86 | 21 | 107 |
| 2019 January | 46 | 12 | 58 |
| 2018 December | 82 | 33 | 115 |
| 2018 November | 91 | 17 | 108 |
| 2018 October | 84 | 8 | 92 |
| 2018 September | 68 | 11 | 79 |
| 2018 August | 56 | 11 | 67 |
| 2018 July | 40 | 13 | 53 |
| 2018 June | 34 | 8 | 42 |
| 2018 May | 44 | 10 | 54 |
| 2018 April | 44 | 13 | 57 |
| 2018 March | 34 | 10 | 44 |
| 2018 February | 42 | 6 | 48 |
| 2018 January | 28 | 8 | 36 |
| 2017 December | 50 | 7 | 57 |
| 2017 November | 33 | 10 | 43 |
| 2017 October | 28 | 6 | 34 |
| 2017 September | 27 | 8 | 35 |
| 2017 August | 28 | 6 | 34 |
| 2017 July | 28 | 9 | 37 |
| 2017 June | 20 | 8 | 28 |
| 2017 May | 28 | 14 | 42 |
| 2017 April | 21 | 10 | 31 |
| 2017 March | 24 | 4 | 28 |
| 2017 February | 22 | 17 | 39 |
| 2017 January | 19 | 14 | 33 |
| 2016 December | 53 | 8 | 61 |
| 2016 November | 58 | 12 | 70 |
| 2016 October | 88 | 11 | 99 |
| 2016 September | 101 | 5 | 106 |
| 2016 August | 166 | 4 | 170 |
| 2016 July | 147 | 9 | 156 |
| 2016 June | 131 | 0 | 131 |
| 2016 May | 133 | 0 | 133 |
| 2016 April | 91 | 0 | 91 |
| 2016 March | 77 | 0 | 77 |
| 2016 February | 88 | 0 | 88 |
| 2016 January | 70 | 0 | 70 |
| 2015 December | 101 | 0 | 101 |
| 2015 November | 84 | 0 | 84 |
| 2015 October | 75 | 0 | 75 |
| 2015 September | 55 | 0 | 55 |
| 2015 August | 65 | 0 | 65 |
| 2015 July | 56 | 0 | 56 |
| 2015 June | 30 | 0 | 30 |
| 2015 May | 45 | 0 | 45 |
| 2015 April | 8 | 0 | 8 |
Show all
